Skip to main content
Erschienen in: Current Atherosclerosis Reports 8/2014

01.08.2014 | Nutrition (JP Foreyt, Section Editor)

Dietary Trans Fatty Acids and Cardiovascular Disease Risk: Past and Present

verfasst von: Alice H. Lichtenstein

Erschienen in: Current Atherosclerosis Reports | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Dietary trans double bond containing fatty acids have been associated with increased risk of cardiovascular disease. There are two main sources of dietary trans fatty acids: meat and dairy fats, and partially hydrogenated fats. Because of a number of factors, including changes in federal labeling requirements for packaged foods, and local bans and grassroots pressure on the use of partially hydrogenated fat, trans fat intake has declined in recent years. Similar to saturated fatty acids, trans fatty acids increase plasma low density lipoprotein (LDL)-cholesterol concentrations. In contrast to saturated fatty acids, trans fatty acids do not increase high density lipoprotein (HDL)-cholesterol concentrations. These differences have been attributed to lipoprotein catabolic rate rather than production rate. When reported, effects of partially hydrogenated fat on glucose homeostasis, C-reactive protein, blood pressure, and LDL oxidation are modest. Although at this time some issues remain unresolved regarding trans fatty acids and CVD risk factors other than plasma lipoprotein concentrations, they should not affect the final dietary recommendation to limit intake.
Literatur
1.
Zurück zum Zitat Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis. 1997;135(1):1–7.PubMedCrossRef Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis. 1997;135(1):1–7.PubMedCrossRef
2.
Zurück zum Zitat Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82–96.PubMedCrossRef Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82–96.PubMedCrossRef
4.
Zurück zum Zitat Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7:e1000252.PubMedCentralPubMedCrossRef Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7:e1000252.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Baum SJ, Kris-Etherton P, Willett WC, Lichtenstein AH, Rudel LL, Maki KC, et al. Fatty acids in acrdiovascular health and disease: a comprehensive update. J Clin Lipidol. 2012;6:216–34.PubMedCrossRef Baum SJ, Kris-Etherton P, Willett WC, Lichtenstein AH, Rudel LL, Maki KC, et al. Fatty acids in acrdiovascular health and disease: a comprehensive update. J Clin Lipidol. 2012;6:216–34.PubMedCrossRef
6.
Zurück zum Zitat Matthan NR, Welty FK, Barrett PH, Harausz C, Dolnikowski GG, Parks JS, et al. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol. 2004;24(6):1092–7. doi:10.1161/01.ATV.0000128410.23161.be.PubMedCrossRef Matthan NR, Welty FK, Barrett PH, Harausz C, Dolnikowski GG, Parks JS, et al. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol. 2004;24(6):1092–7. doi:10.​1161/​01.​ATV.​0000128410.​23161.​be.PubMedCrossRef
7.
Zurück zum Zitat Eckel RH, Borra S, Lichtenstein AH, Yin-Piazza SY. Understanding the complexity of trans fatty acid reduction in the American diet. Circulation. 2007;115:2231–46.PubMedCrossRef Eckel RH, Borra S, Lichtenstein AH, Yin-Piazza SY. Understanding the complexity of trans fatty acid reduction in the American diet. Circulation. 2007;115:2231–46.PubMedCrossRef
8.
Zurück zum Zitat Gebauer SK, Chardigny JM, Jakobsen MU, Lamarche B, Lock AL, Proctor SD, et al. Effects of ruminant trans fatty acids on cardiovascular disease and cancer: a comprehensive review of epidemiological, clinical, and mechanistic studies. Adv Nutr. 2011;2:332–54.PubMedCentralPubMedCrossRef Gebauer SK, Chardigny JM, Jakobsen MU, Lamarche B, Lock AL, Proctor SD, et al. Effects of ruminant trans fatty acids on cardiovascular disease and cancer: a comprehensive review of epidemiological, clinical, and mechanistic studies. Adv Nutr. 2011;2:332–54.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354(15):1601–13.PubMedCrossRef Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354(15):1601–13.PubMedCrossRef
10.
Zurück zum Zitat Lefevre M, Mensink RP, Kris-Etherton PM, Petersen B, Smith K, Flickinger BD. Predicted changes in fatty acid intakes, plasma lipids, and cardiovascular disease risk following replacement of trans fatty acid-containing soybean oil with application-appropriate alternatives. Lipids. 2012;47(10):951–62. doi:10.1007/s11745-012-3705-y.PubMedCentralPubMedCrossRef Lefevre M, Mensink RP, Kris-Etherton PM, Petersen B, Smith K, Flickinger BD. Predicted changes in fatty acid intakes, plasma lipids, and cardiovascular disease risk following replacement of trans fatty acid-containing soybean oil with application-appropriate alternatives. Lipids. 2012;47(10):951–62. doi:10.​1007/​s11745-012-3705-y.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Doell D, Folmer H, Lee HR, Honigfort M, Carberry S. Updated esimtate of trans fat intake by the US population. Food Addit Contam. 2012;29:861–74.CrossRef Doell D, Folmer H, Lee HR, Honigfort M, Carberry S. Updated esimtate of trans fat intake by the US population. Food Addit Contam. 2012;29:861–74.CrossRef
13.
Zurück zum Zitat Food and Drug Administration. Food labeling: trans fatty acids in nutrition labeling, nutrient content claims, and health claims. Final rule. Fed Regist. 2003;133:41433–14506. Food and Drug Administration. Food labeling: trans fatty acids in nutrition labeling, nutrient content claims, and health claims. Final rule. Fed Regist. 2003;133:41433–14506.
14.
Zurück zum Zitat Rahkovsky I, Martinez S, Kuchler F. New food choices free of trans fats better align U.S. diets with health recommendations. Economic Information Bulletin Number 95, USDA. 2012. Rahkovsky I, Martinez S, Kuchler F. New food choices free of trans fats better align U.S. diets with health recommendations. Economic Information Bulletin Number 95, USDA. 2012.
16.•
Zurück zum Zitat Angell SY, Cobb LK, Curis CJ, Konty KJ, Silver LD. Change in trans fatty acid content of fast food purchases associated with New York City's restaurant regulation. Annal of Internal Medicine. 2012. This study demonstrated that restricting the use of partially-hydrogenated fat in New York City dramatically decreased the mean trans fatty acid content of food purchased from fast-food restaurants. Angell SY, Cobb LK, Curis CJ, Konty KJ, Silver LD. Change in trans fatty acid content of fast food purchases associated with New York City's restaurant regulation. Annal of Internal Medicine. 2012. This study demonstrated that restricting the use of partially-hydrogenated fat in New York City dramatically decreased the mean trans fatty acid content of food purchased from fast-food restaurants.
17.
Zurück zum Zitat Food and Drug Administration. FDA takes step to further reduce trans fats in processed foods. 2013. Food and Drug Administration. FDA takes step to further reduce trans fats in processed foods. 2013.
18.•
Zurück zum Zitat Vesper HW, Kuiper HC, Mirel LB, Johnson CL, Pirkle JL. Levels of plasma trans-fatty acids in non-hispanic white adults in the United States in 2000 and 2009. JAMA. 2012;307:562. The findings of this study demonstrate that secular changes in the use of partially-hydrogenated fat in the food supply has an effect on a measurable biomarker, plasma trans fatty acid concentration.PubMedCrossRef Vesper HW, Kuiper HC, Mirel LB, Johnson CL, Pirkle JL. Levels of plasma trans-fatty acids in non-hispanic white adults in the United States in 2000 and 2009. JAMA. 2012;307:562. The findings of this study demonstrate that secular changes in the use of partially-hydrogenated fat in the food supply has an effect on a measurable biomarker, plasma trans fatty acid concentration.PubMedCrossRef
22.
Zurück zum Zitat Temme EH, Millenaar IL, Van Donkersgoed G, Westenbrink S. Impact of fatty acid food reformulations on intake of Dutch young adults. Acta Cardiol. 2011;66:721–8.PubMed Temme EH, Millenaar IL, Van Donkersgoed G, Westenbrink S. Impact of fatty acid food reformulations on intake of Dutch young adults. Acta Cardiol. 2011;66:721–8.PubMed
23.
Zurück zum Zitat Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77(5):1146–55.PubMed Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77(5):1146–55.PubMed
24.
Zurück zum Zitat Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans fatty acids and coronary heart disease. N Engl J Med. 1999;340(25):1994–8.PubMedCrossRef Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans fatty acids and coronary heart disease. N Engl J Med. 1999;340(25):1994–8.PubMedCrossRef
25.
Zurück zum Zitat Lichtenstein AH, Ausman LA, Jalbert SM, Schaefer EJ. Comparison of different forms of hydrogenated fats on serum lipid levels in moderately hypercholesterolemic female and male subjects. N Engl J Med. 1999;340:1933–40.PubMedCrossRef Lichtenstein AH, Ausman LA, Jalbert SM, Schaefer EJ. Comparison of different forms of hydrogenated fats on serum lipid levels in moderately hypercholesterolemic female and male subjects. N Engl J Med. 1999;340:1933–40.PubMedCrossRef
26.
Zurück zum Zitat Han SN, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res. 2002;43(3):445–52.PubMed Han SN, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res. 2002;43(3):445–52.PubMed
27.
28.
Zurück zum Zitat Aronis KN, Joseph RJ, Blackburn GL, Mantzoros C. Trans-fatty acids, insulin resistance/diabetes, and cardiovascular disease risk: should policy decisions be based on observational cohort studies, or should we be waiting for results from randomized placebo-controlled trials? Metab Clin Exp. 2011;60(7):901–5. doi:10.1016/j.metabol.2011.04.003.PubMedCrossRef Aronis KN, Joseph RJ, Blackburn GL, Mantzoros C. Trans-fatty acids, insulin resistance/diabetes, and cardiovascular disease risk: should policy decisions be based on observational cohort studies, or should we be waiting for results from randomized placebo-controlled trials? Metab Clin Exp. 2011;60(7):901–5. doi:10.​1016/​j.​metabol.​2011.​04.​003.PubMedCrossRef
29.
Zurück zum Zitat Bendsen NT, Christensen R, Bartels EM, Astrup A. Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. Eur J Clin Nutr. 2011;65:773–83.PubMedCrossRef Bendsen NT, Christensen R, Bartels EM, Astrup A. Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. Eur J Clin Nutr. 2011;65:773–83.PubMedCrossRef
31.
Zurück zum Zitat Matthan NR, Ausman LM, Lichtenstein AH, Jones PJ. Hydrogenated fat consumption affects cholesterol synthesis in moderately hypercholesterolemic women. J Lipid Res. 2000;41(5):834–9.PubMed Matthan NR, Ausman LM, Lichtenstein AH, Jones PJ. Hydrogenated fat consumption affects cholesterol synthesis in moderately hypercholesterolemic women. J Lipid Res. 2000;41(5):834–9.PubMed
32.
Zurück zum Zitat Cuchel M, Schwab US, Jones PJ, Vogel S, Lammi-Keefe C, Li Z, et al. Impact of hydrogenated fat consumption on endogenous cholesterol synthesis and susceptibility of low-density lipoprotein to oxidation in moderately hypercholesterolemic individuals. Metab Clin Exp. 1996;45(2):241–7.PubMedCrossRef Cuchel M, Schwab US, Jones PJ, Vogel S, Lammi-Keefe C, Li Z, et al. Impact of hydrogenated fat consumption on endogenous cholesterol synthesis and susceptibility of low-density lipoprotein to oxidation in moderately hypercholesterolemic individuals. Metab Clin Exp. 1996;45(2):241–7.PubMedCrossRef
33.
Zurück zum Zitat Lichtenstein AH, Jauhiainen M, McGladdery S, Ausman LM, Jalbert SM, Vilella-Bach M, et al. Impact of hydrogenated fat on high density lipoprotein subfractions and metabolism. J Lipid Res. 2001;42(4):597–604.PubMed Lichtenstein AH, Jauhiainen M, McGladdery S, Ausman LM, Jalbert SM, Vilella-Bach M, et al. Impact of hydrogenated fat on high density lipoprotein subfractions and metabolism. J Lipid Res. 2001;42(4):597–604.PubMed
35.
Zurück zum Zitat Mauger JF, Lichtenstein AH, Ausman LM, Jalbert SM, Jauhiainen M, Ehnholm C, et al. Effect of different forms of dietary hydrogenated fats on LDL particle size. Am J Clin Nutr. 2003;78(3):370–5.PubMed Mauger JF, Lichtenstein AH, Ausman LM, Jalbert SM, Jauhiainen M, Ehnholm C, et al. Effect of different forms of dietary hydrogenated fats on LDL particle size. Am J Clin Nutr. 2003;78(3):370–5.PubMed
36.
Zurück zum Zitat Lichtenstein AH, Erkkila AT, Lamarche B, Schwab US, Jalbert SM, Ausman LM. Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. Atherosclerosis. 2003;171(1):97–107.PubMedCrossRef Lichtenstein AH, Erkkila AT, Lamarche B, Schwab US, Jalbert SM, Ausman LM. Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. Atherosclerosis. 2003;171(1):97–107.PubMedCrossRef
38.
Zurück zum Zitat Matthan NR, Cianflone K, Lichtenstein AH, Ausman LM, Jauhiainen M, Jones PJ. Hydrogenated fat consumption affects acylation-stimulating protein levels and cholesterol esterification rates in moderately hypercholesterolemic women. J Lipid Res. 2001;42(11):1841–8.PubMed Matthan NR, Cianflone K, Lichtenstein AH, Ausman LM, Jauhiainen M, Jones PJ. Hydrogenated fat consumption affects acylation-stimulating protein levels and cholesterol esterification rates in moderately hypercholesterolemic women. J Lipid Res. 2001;42(11):1841–8.PubMed
39.
Zurück zum Zitat Booth SL, Davidson KW, Lichtenstein AH, Sadowski JA. Plasma concentrations of dihydro-vitamin K1 following dietary intake of a hydrogenated vitamin K1-rich vegetable oil. Lipids. 1996;31(7):709–13.PubMedCrossRef Booth SL, Davidson KW, Lichtenstein AH, Sadowski JA. Plasma concentrations of dihydro-vitamin K1 following dietary intake of a hydrogenated vitamin K1-rich vegetable oil. Lipids. 1996;31(7):709–13.PubMedCrossRef
40.
Zurück zum Zitat Erkkila AT, Booth SL, Hu FB, Jacques PF, Manson JE, Rexrode KM, et al. Phylloquinone intake as a marker for coronary heart disease risk but not stroke in women. Eur J Clin Nutr. 2005;59:196–204.PubMedCrossRef Erkkila AT, Booth SL, Hu FB, Jacques PF, Manson JE, Rexrode KM, et al. Phylloquinone intake as a marker for coronary heart disease risk but not stroke in women. Eur J Clin Nutr. 2005;59:196–204.PubMedCrossRef
41.
Zurück zum Zitat Erkkila AT, Lichtenstein AH, Jacques PF, Hu FB, Wilson PW, Booth SL. Determinants of plasma dihydrophylloquinone in men and women. Br J Nutr. 2005;93(5):701–8.PubMedCrossRef Erkkila AT, Lichtenstein AH, Jacques PF, Hu FB, Wilson PW, Booth SL. Determinants of plasma dihydrophylloquinone in men and women. Br J Nutr. 2005;93(5):701–8.PubMedCrossRef
42.
Zurück zum Zitat de Roos B, Wanders AJ, Wood S, Horgan G, Rucklige G, Reid M, et al. A high intake of industrial or ruminant trans fatty acids does not affect the plasma proteome in healthy men. Proteomics. 2011;11(19):3928–34. doi:10.1002/pmic.201100163.PubMedCrossRef de Roos B, Wanders AJ, Wood S, Horgan G, Rucklige G, Reid M, et al. A high intake of industrial or ruminant trans fatty acids does not affect the plasma proteome in healthy men. Proteomics. 2011;11(19):3928–34. doi:10.​1002/​pmic.​201100163.PubMedCrossRef
43.
44.
Zurück zum Zitat Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323(7):439–45.PubMedCrossRef Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323(7):439–45.PubMedCrossRef
49.•
Zurück zum Zitat Kiage JN, Merrill PD, Robinson CJ, Cao Y, Malik TA, Hundley BC, et al. Intake of trans fat and all-cause mortality in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) cohort. Am J Clin Nutr. 2013;97(5):1121–8. doi:10.3945/ajcn.112.049064. The data from this study indicated that in a racially and ethnically diverse group of individuals living in the U.S. higher trans fat intake was associated with an increased risk of all-cause mortality.PubMedCentralPubMedCrossRef Kiage JN, Merrill PD, Robinson CJ, Cao Y, Malik TA, Hundley BC, et al. Intake of trans fat and all-cause mortality in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) cohort. Am J Clin Nutr. 2013;97(5):1121–8. doi:10.​3945/​ajcn.​112.​049064. The data from this study indicated that in a racially and ethnically diverse group of individuals living in the U.S. higher trans fat intake was associated with an increased risk of all-cause mortality.PubMedCentralPubMedCrossRef
50.
Zurück zum Zitat Brouwer IA, Wanders AJ, Katan BM. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans–a quantitative review. PLoS One. 2010;5:e9434.PubMedCentralPubMedCrossRef Brouwer IA, Wanders AJ, Katan BM. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans–a quantitative review. PLoS One. 2010;5:e9434.PubMedCentralPubMedCrossRef
51.
Zurück zum Zitat Laake I, Pedersen JI, Selmer R, Kirkhus B, Lindman AS, Tverdal A, et al. A prospective study of intake of trans-fatty acids from ruminant fat, partially hydrogenated vegetable oils, and marine oils and mortality from CVD. Br J Nutr. 2012;108(4):743–54. doi:10.1017/S0007114511005897.PubMedCrossRef Laake I, Pedersen JI, Selmer R, Kirkhus B, Lindman AS, Tverdal A, et al. A prospective study of intake of trans-fatty acids from ruminant fat, partially hydrogenated vegetable oils, and marine oils and mortality from CVD. Br J Nutr. 2012;108(4):743–54. doi:10.​1017/​S000711451100589​7.PubMedCrossRef
53.
Zurück zum Zitat Eckel RH, Jakicic JM, Ard JD, Hubbard VS, de Jesus JM, Lee IM, et al. AHA/acc guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi:10.1161/01.cir.0000437740.48606.d1. Eckel RH, Jakicic JM, Ard JD, Hubbard VS, de Jesus JM, Lee IM, et al. AHA/acc guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi:10.​1161/​01.​cir.​0000437740.​48606.​d1.
54.
Zurück zum Zitat Lichtenstein AH. New York City trans fat ban: improving the default option when purchasing foods prepared outside of the home. Annal Intern Med. 2012;157:144–5.CrossRef Lichtenstein AH. New York City trans fat ban: improving the default option when purchasing foods prepared outside of the home. Annal Intern Med. 2012;157:144–5.CrossRef
Metadaten
Titel
Dietary Trans Fatty Acids and Cardiovascular Disease Risk: Past and Present
verfasst von
Alice H. Lichtenstein
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 8/2014
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-014-0433-1

Weitere Artikel der Ausgabe 8/2014

Current Atherosclerosis Reports 8/2014 Zur Ausgabe

Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)

New Risk Markers for Cardiovascular Prevention

Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)

HDL: To Treat or Not To Treat?

Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)

Thrombus Aspiration in Primary Angioplasty for ST-segment Elevation Myocardial Infarction

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.